相关实验视频

Updated: Jun 13, 2025

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

TMEM100作为TAK1受体起作用,防止病理性心脏缩进展

Bin-Bin Zhang¹, Yi-Lin Zhao², Yan-Yu Lu¹

¹Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, No.1 Jianshe East Road, Zhengzhou, China.

Cell communication and signaling : CCS

|September 11, 2024

概括

跨膜蛋白100 (TMEM100) 通过抑制TAK1-JNK/p38通路,防止病态心脏缩. 这一发现表明TMEM100是心力衰竭治疗的潜在治疗标.

科学领域:

心血管生物学心血管生物学
分子医学是分子医学.
细胞信号传输细胞信号传输

背景情况:

病理性心脏缩是心力衰竭的主要原因之一,其机制尚不完全理解.
跨膜蛋白100 (TMEM100) 在心脏缩中的作用以前没有被研究过.
已知TMEM100参与其他细胞过程和疾病.

研究的目的:

为了研究TMEM100在病理性心脏缩中的作用.
阐明TMEM100在心脏中的功能背后的分子机制.
评估TMEM100作为心脏缩的潜在治疗标.

主要方法:

利用腺相关病毒9 (AAV9) 在经过横向大动脉收缩 (TAC) 的小鼠中过度表达TMEM100.
采用腺病毒TMEM100 (AdTMEM100) 进行基 (PE) 诱导心肌细胞缩的体外研究和TMEM100倒置实验.
进行RNA测序和分子分析,分析信号通路和蛋白质相互作用,包括TAK1抑制.

主要成果:

发现TMEM100在心脏缩时被上调.
过度表达TMEM100减弱TAC诱导的心脏缩和改善心脏功能.
在体外,TMEM100抑制了PE诱导的心肌细胞缩,并与TAK1相互作用以抑制TAK1-JNK/p38通路.

结论:

TMEM100对病理性心脏缩起着保护作用.
保护机制包括抑制TAK1-JNK/p38信号通路.
TMEM100代表了治疗心脏缩和预防心力衰竭的有希望的治疗标.

关键词:

心脏过度缩小的心脏过度缩小心肌细胞过度缩蛋白质蛋白质相互作用这就是TAK1的意义.TMEM100 TMEM100 的使用方法

更多相关视频

Transverse Aortic Constriction in Mice

Transverse Aortic Constriction in Mice

Published on: April 21, 2010

Isolation, Culture, and Functional Characterization of Adult Mouse Cardiomyoctyes

Isolation, Culture, and Functional Characterization of Adult Mouse Cardiomyoctyes

Published on: September 24, 2013

相关概念视频

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Enzyme-linked Receptors

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...

TGF - β Signaling Pathway

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...